Edesa Biotech, Inc. reported earnings results for the full year ended September 30, 2022. For the full year, the company reported net loss was USD 17.55 million compared to USD 13.34 million a year ago. Basic loss per share from continuing operations was USD 7.35 compared to USD 7.7 a year ago.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
4.52 USD | -0.22% | -0.66% | -1.09% |
May. 10 | Edesa Biotech, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended March 31, 2024 | CI |
Mar. 05 | Top Premarket Gainers | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-1.09% | 14.57M | |
+7.70% | 111B | |
+11.19% | 106B | |
-12.35% | 22.24B | |
+0.44% | 21.25B | |
-4.18% | 18.97B | |
-37.85% | 18.52B | |
-8.92% | 16.81B | |
+38.38% | 12.54B | |
-24.66% | 8.09B |
- Stock Market
- Equities
- EDSA Stock
- News Edesa Biotech, Inc.
- Edesa Biotech, Inc. Reports Earnings Results for the Full Year Ended September 30, 2022